Artículo
Tuberculosis treatment without rifampin in kidney/kidney–pancreas transplantation: A case series report
Radisic, Marcelo Victor; Pujato, Natalia Rosana; Bravo, Pablo Martin; del Grosso, Roxana Constanza; Hunter, Martin; Beltramino, Santiago; Linares González, Laura; Cornet, María Lucía; del Carmen Rial, Maria; Franzini, Rosa Livia; Dotta, Ana C.; León, Luis Roberto; Walther, Javier; Uva, Pablo Daniel
; Werber, Gustavo
Fecha de publicación:
12/2022
Editorial:
Wiley Blackwell Publishing, Inc
Revista:
Transplant Infectious Disease
ISSN:
1398-2273
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Background: The best approach to tuberculosis (TB) treatment in transplanted patients is still unknown. Current guidelines are based on evidence either extrapolated from other populations or observational. Rifampin-containing regimens have strong pharmacokinetic interactions with immunosuppressive regimens, with high rates of organ dysfunction and ∼20% mortality. This report describes the results obtained using non-rifampin-containing regimens to treat confirmed TB in adult patients with kidney/kidney–pancreas transplantation. Methods: Retrospective data analysis from confirmed TB cases in adult kidney/kidney–pancreas transplant recipients (2006–2019), treated “de novo” with non-rifampin-containing regimens. Results: Fifty-seven patients had confirmed TB. Thirty patients were treated “de novo” with non-rifampin-containing regimens. These patients’ mean age was 49.24 (±11.50) years. Induction immunosuppression was used in 22 patients. Maintenance immunosuppression was tacrolimus–mycophenolate–steroids in 13 (43%), sirolimus–mycophenolate–steroids in 6 (20%), and other immunosuppressive regimens in 11 (36%). Belatacept was used in four patients. TB localizations: pulmonary 43%; disseminated 23%; extrapulmonary 33%. Twenty-seven (90%) patients completed treatment with isoniazid, ethambutol, and levofloxacin (12 months, 23; 9 months, 3; 6 months, 1); 12 of these patients also received pyrazinamide for the first 2 months and were cured with functioning grafts. One patient (3%) lost the graft while on treatment. Two patients (7%) died while on TB treatment. Median (range) follow-up after completion of TB treatment was 32 (8–150) months. No TB relapses were observed. Conclusions: Results with non-rifampin-containing TB treatments in this case series were better (in terms of mortality and graft dysfunction) than those previously described with rifampin-containing regimens in transplanted patients.
Palabras clave:
QUINOLONES
,
RIFAMPIN
,
SOLID ORGAN TRANSPLANTATION
,
TREATMENT
,
TUBERCULOSIS
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Articulos de SEDE CENTRAL
Citación
Radisic, Marcelo Victor; Pujato, Natalia Rosana; Bravo, Pablo Martin; del Grosso, Roxana Constanza; Hunter, Martin; et al.; Tuberculosis treatment without rifampin in kidney/kidney–pancreas transplantation: A case series report; Wiley Blackwell Publishing, Inc; Transplant Infectious Disease; 24; 6; 12-2022; 1-11
Compartir
Altmétricas